DaVita (NYSE:DVA) Given New $164.00 Price Target at Truist Financial

DaVita (NYSE:DVA) had its price target lowered by equities research analysts at Truist Financial from $170.00 to $164.00 in a report issued on Monday,Benzinga reports. The firm currently has a “hold” rating on the stock. Truist Financial’s target price would indicate a potential upside of 12.93% from the company’s previous close.

A number of other equities research analysts have also recently commented on the company. Barclays lifted their target price on DaVita from $164.00 to $169.00 and gave the stock an “equal weight” rating in a research note on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research note on Friday, February 21st. Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, StockNews.com upgraded DaVita from a “hold” rating to a “buy” rating in a research note on Friday, April 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $164.50.

DaVita Price Performance

Shares of NYSE:DVA opened at $145.23 on Monday. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock’s fifty day simple moving average is $145.68 and its two-hundred day simple moving average is $153.57. DaVita has a 1-year low of $131.44 and a 1-year high of $179.60. The stock has a market cap of $11.16 billion, a PE ratio of 13.52, a price-to-earnings-growth ratio of 1.07 and a beta of 1.14.

DaVita (NYSE:DVA) last issued its quarterly earnings data on Monday, May 12th. The company reported $2.00 earnings per share for the quarter, beating the consensus estimate of $1.75 by $0.25. DaVita had a return on equity of 115.48% and a net margin of 7.31%. The business had revenue of $3.22 billion for the quarter, compared to analysts’ expectations of $3.22 billion. During the same period last year, the business earned $2.26 EPS. The business’s revenue was up 5.0% on a year-over-year basis. As a group, analysts forecast that DaVita will post 10.76 EPS for the current fiscal year.

Institutional Investors Weigh In On DaVita

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Invesco Ltd. raised its stake in DaVita by 3.4% in the 1st quarter. Invesco Ltd. now owns 1,642,947 shares of the company’s stock valued at $251,322,000 after acquiring an additional 53,402 shares during the period. Northern Trust Corp raised its stake in DaVita by 20.2% in the 1st quarter. Northern Trust Corp now owns 890,632 shares of the company’s stock valued at $136,240,000 after acquiring an additional 149,858 shares during the period. Gates Capital Management Inc. raised its stake in DaVita by 0.7% in the 1st quarter. Gates Capital Management Inc. now owns 722,205 shares of the company’s stock valued at $110,476,000 after acquiring an additional 4,698 shares during the period. Amundi raised its stake in DaVita by 16.0% in the 1st quarter. Amundi now owns 517,690 shares of the company’s stock valued at $79,584,000 after acquiring an additional 71,304 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in DaVita by 14.0% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company’s stock valued at $69,697,000 after acquiring an additional 57,386 shares during the period. 90.12% of the stock is currently owned by institutional investors.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.